Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

93.30
+2.152.36%
Volume:1.31M
Turnover:119.84M
Market Cap:12.24B
PE:-28.10
High:93.70
Open:87.91
Low:86.42
Close:91.15
52wk High:120.74
52wk Low:36.36
Shares:131.17M
Float Shares:126.00M
Volume Ratio:0.67
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3203
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-15.59%
PB:-123.24
PE(LYR):-28.10

Loading ...

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

THOMSON REUTERS
·
Nov 10, 2025

U.S. RESEARCH ROUNDUP-DoorDash, Honeywell, Zscaler

Reuters
·
Nov 10, 2025

RBC Capital Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Nov 08, 2025

Cantor Fitzgerald Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
Nov 07, 2025

Positive Outlook on GH Research Amidst Clinical Challenges and Future Growth Potential

TIPRANKS
·
Nov 07, 2025

Guardant Health to Participate in Jefferies Global Healthcare Conference

Reuters
·
Nov 07, 2025

Guardant Health Grants RSUs and Stock Options to New Employees Under Inducement Plan

Reuters
·
Nov 07, 2025

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 07, 2025

GH Research: Stable Financials and Promising Clinical Progress Support Buy Rating

TIPRANKS
·
Nov 07, 2025

Psychedelic: Compass Pathways, GH Research report Q3 earnings

TIPRANKS
·
Nov 07, 2025

Guardant Reveal Blood Test Detects Chemotherapy Response Earlier Than Conventional Methods

Reuters
·
Nov 06, 2025

Guardant Health: Rise in Tumor Signal Identified Disease Progression up to 18 Months Earlier With Median Lead Time of 2.3 Months

THOMSON REUTERS
·
Nov 06, 2025

Guardant Health: Patients Who Experienced Over 98% Reduction in Tumor Signal Saw Most Significant Benefits

THOMSON REUTERS
·
Nov 06, 2025

New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response

THOMSON REUTERS
·
Nov 06, 2025

GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate

Benzinga
·
Nov 06, 2025

GH Research reports Q3 EPS (23c), consensus (23c)

TIPRANKS
·
Nov 06, 2025

Press Release: GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Dow Jones
·
Nov 06, 2025

Assessing Guardant Health After Stock Surges 275% on New Cancer Screening Advances

Simply Wall St.
·
Nov 06, 2025

Guardant Health Shield CRC Blood Test Achieves 95% Adherence in 20,000-Patient Study

Reuters
·
Nov 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Bunge, O'Reilly Automotive, Targa Resources

Reuters
·
Nov 06, 2025